FDA Regulatory Progress Update - Conference Call

FDA Regulatory Progress Update - Conference Call

Please click on the following link to access the audio stream for the conference call.

http://www.openbriefing.com/OB/2018.aspx

 

Resignation of Non-Executive Director

Resignation of Non-Executive Director

Non-Executive Director, Dr Mel Bridges will leave Tissue Therapies on Wednesday, 25 November 2015.

Resignation of Non-Executive Director

Dr Christian Behrenbruch appointed Executive Director

Dr Christian Behrenbruch appointed Executive Director

Dr Christian Behrenbruch commences as Executive Director bringing a wealth of practical biotech experience.

Dr Christian Behrenbruch appointed Executive Director

14-9-2015 Further Information regarding new research agreement with QUT

14-9-2015 Further Information regarding new research agreement with QUT

Tissue Therapies Ltd and Queensland University of Technology (QUT) have a  long-­?term collaborative  relationship  with  QUT  having  a  2.67%  equity   investment   in  Tissue Therapies. With QUT’s full support, a new R&D agreement has  been signed taking that relationship to a more innovative level consistent with the  advanced  development  of VitroGro®. 

14-9-2015 Further Information regarding new research agreement with QUT

18-8-2015 Company Secretary Appointment

18-8-2015 Company Secretary Appointment

Tissue Therapies (ASX:TIS), is pleased to announce the appointment Ms Saskia Jo as Company Secretary. Ms Jo is a CPA and Chartered Secretaries of Australia member, and previously spent more than three years as Tissue Therapies’ Corporate Accountant.

Ms Jo replaces Mr Drummond McKenzie who served as Tissue Therapies’ Company Secretary from 2003 to 2015.

 

18-8-2015 Company Secretary Appointment

Tissue Therapies Limited is a heath biotechnology company that develops and manufactures synthetic proteins for wound healing applications.

Tissue Therapies Limited is commercialising VitroGro® ECM for the treatment of venous leg ulcers and diabetic foot ulcers. VitroGro® is a broad spectrum healing promoter for the treatment of ulcers of all severity.

[Intellectual Property]

Tissue Therapies Limited's shares are traded on the Australian, Berlin and Frankfurt stock exchanges.

News

FDA Regulatory Progress Update - Conference Call

Please click on the following link to access the audio stream for the conference call.

http://www.openbriefing.com/OB/2018.aspx

 

... More

Resignation of Non-Executive Director

Non-Executive Director, Dr Mel Bridges will leave Tissue Therapies on Wednesday, 25 November 2015.

... More

Dr Christian Behrenbruch appointed Executive Director

Dr Christian Behrenbruch commences as Executive Director bringing a wealth of practical biotech experience.

... More

14-9-2015 Further Information regarding new research agreement with QUT

Tissue Therapies Ltd and Queensland University of Technology (QUT) have a  long-­?term collaborative  relationship  with  QUT  having  a  2.67%  equity   investment   in  Tissue Therapies. With QUT’s full support, a new R&D agreement has  been signed taking that relationship to a more innovative level consistent with... More

18-8-2015 Company Secretary Appointment

Tissue Therapies (ASX:TIS), is pleased to announce the appointment Ms Saskia Jo as Company Secretary. Ms Jo is a CPA and Chartered Secretaries of Australia member, and previously spent more than three years as Tissue Therapies’ Corporate Accountant.

Ms Jo replaces Mr Drummond McKenzie who served as Tissue Therapies’ Company Secretary from 2003 to 2015.

 

... More

Tissue Therapies Limited has identified that there is a significant need in wound care for improving the outcome of hard to heal wounds. Hard to heal wounds are defined as wounds that have not respond to standard therapy in an orderly and timely manner [1]. This type of delayed healing occurs in a variety of wound types (venous leg ulcers, arterial leg ulcers, mixed leg ulcers, diabetic foot ulcers and pressure ulcers) [1,2,3].

Treatment of hard to heal wounds is demanding on both patients and healthcare providers, with significant financial impact on the healthcare systems and the patients quality of life. For example, conservative costs to the UK National Health Service (NHS) are estimated at £2-3 billion per year. In the United States hard to heal wounds effect 6.5 million patients and is estimated to cost in excess of US$25 billion annually [4].

In Germany, according to cautious estimates, approximately 3-4 million people suffer from hard to heal wounds and costs associated are high for the Statutory Health Insurance (SHI) funds, the economy and patients [5]. The average annual cost to the SHI per patient for the treatment of venous leg ulcers alone was estimated at €7630.70 and the annual cost to the patient was estimated at €1027 [5].

About VitroGro® ECM animation

About VitroGro® ECM animation

 

Asx share price Berlin share price Frankfurt share price

In 2007, a UK hospital audit found that the drivers behind such high costs were[6];

  1. The relatively high incidence of non-healing wounds (1 in 4 wounds had been non-healing for at least six months);
  2. The prevalence of infections associated with non-healing wounds, resulting in longer hospital related care;
  3. Nursing time, which was associated 33-41% of the total cost of care and the cost of wound dressings, which were associated with 17-22% of the total cost of care.
Clearly there is an opportunity to provide a technological solution that reduces the time and resources taken to resolve hard to heal wounds, in addition to providing improved patient outcomes.

VitroGro® ECM is a new treatment for hard to heal wounds that is used in conjunction with standard care including moist wound dressing and compression. We see opportunities to have significant impact in wound care markets in Asia, Australia, Canada, Europe, New Zealand, the United States and other markets experiencing the economic burden of wound care. [learn more]


[1] Vowden P. Hard to heal wounds made easy. Wounds International 2011
[2] Srinivasaiah N. et al. A point prevalence survey of wounds in the North East of England. J. Wound Care 2007
[3] Vowden KR. and Vowden P. The prevalence, management, equipment provision and outcomes for patients with pressure ulceration identified in a wound care survey with one English health care district. J. Tissue Viability 2009.
[4] Harding K and Queen D. Chronic wounds and their management and prevention is a significant public health issue. Int. Wound J. 2010
[5] Purwins S et al. Cost of illness of chronic leg ulcers in Germany Int. Wound J. 2010
[6] Drew P et al. The cost of wound care for a local population in England. Int. Wound J. 2007